For the first time, we demonstrated that patients with refractory esophageal or head/neck squamous cell carcinoma that co-expressed MAGE-A4 and NY-ESO-1 had significantly worse prognosis than patients with tumors expressing MAGE-A4 alone. The gene discussed is MAGEA4; the disease is head and neck squamous cell carcinoma.